• Home
  • Investor Overview & Financial Information

Investor Overview & Financial Information

Aspira is Transforming Women's Health

with Innovative Solutions

Investor News

View More

  • Aspira Women’s Health Releases Analytical and Initial Clinical Validation Performance for OVASight at ASCO 2021

    Press Release

    Read More
  • Aspira Women’s Health Inc. to Participate in the William Blair Growth Stock Conference

    Press Release

    Read More
  • Aspira Women’s Health Reports First Quarter 2021 Financial Results

    Press Release

    Read More

Aspira is led by an experienced team of business, medical and scientific professionals with a passion for improving health outcomes for women.

Meet our Leadership Team

About Aspira Women's Health


Our Mission

Aspira Women's Health is helping transform women’s health with the discovery, development, and utilization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. Our FDA-cleared products OVA1® and OVERA® detect the risk of ovarian malignancy in women with adnexal masses. Recently launched, Aspira GenetiXSM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of experience in ovarian cancer risk assessment, Aspira Women's Health has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans.

Learn More

Featured Video

View More

Aspira Women's Health Investor Presentation


June 2021 Investor Presentation

Aspira Women's Health Investor Presentation June 2021 | Download

Investor Resources & Financial Information


Click a tab below to view more information

Investor Relations Group Image

Investor Relations


Ashley R. Robinson,
LifeSci Advisors LLC.
Tel: 617.430.7577
Email: [email protected]

Corporate Governance


Committee Members


Below is a summary of our committee membership information.

Audit CommitteeCompensation CommitteeNomination and Corporate Governance Committee
James T. LaFrance (Board Chairperson)
Valerie Palmieri
Veronica G.H. Jordan, Ph.D.MemberChairperson
David SchreiberChairpersonMember
Nicole SandfordMemberMember
Sandra Brooks, MDMember

Analyst Coverage


Aspira Women's Health is followed by the analysts listed to the right. Please note that any opinions, estimates or forecasts regarding Aspira Women's Health’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Aspira Women's Health or its management. Aspira Women's Health does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Analysts

  • William Blair & Company
  • Cantor Fitzgerald
  • Truist Securities, Inc

Webcasts and Presentations


Aspira Women’s Health, Inc. to Report First Quarter 2021 Financial Results

Thursday, May 13 at 4:30 pm ET
Domestic: 877-407-4018
International: 201-689-8471
Conference ID: 13719197
Webcast: http://public.viavid.com/index.php?id=144631


Aspira Women’s Health, Inc. Key Opinion Leader Call on
Ovarian Cancer Diagnostics, Innovation Pipeline, and Rebranding Initiatives

To register for the webcast and listen to the replay please follow the link below:

Click here to register for the replay


2020 Cantor Virtual Global Healthcare Conference:
September 17, 2020

To register for the webcast and listen to the replay please follow the link below
Webcast: https://www.webcaster4.com/Webcast/Page/2495/37394

SEC Filings


Annual Reports


Contact us to learn more or to speak with investor relations.